4Dec GW.Acute decompensated heart failure:the shrinking role ofinotropic therapy[J].J Am Coll Cordial,2005,46(1):65-67.
5Pollesello P,Papp Z.The cardioprotective effects of levosimendan:preclinical and clinical evidence[J].J Cardiovasc Pharmacol,2007,50(3):257-263.
6Kota B,Prasad AS,Economides C,et al.Levosimendan and calci-um sensitization of the contractile proteins in cardiac muscle:impacton heart failure[J].J Cardiovasc Pharmacol Ther,2008,13(4):269-278.
7Lee SC,Stevens TL,Sandberg SM,et al.The potential of brain na-triuretic peptide as a biomarker for New York Heart Association classduring the outpatient treatment of heart failure[J].J Card Fail,2002,8(3):149-154.
8Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the task force on acute heart failure of the european society of cardiology. Eur Heart J, 2005,26 : 384-416.
9Kopustinskiene DM, Pollesello P, Saris NE. Levosimendan is a mitochondrial KAte channel opener. European Journal of Pharmacology, 2001,428 : 311-314.
10Kersten JR, Montgomery MW, Pagel PS, et al. Levosimendan a new positive inotropic drug, decreases myocardial infarct size viaactivation of KAW channeis. Anesth Analg, 2000,90 : 5-11.
